Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure

BACKGROUND: Dolutegravir is approved for the treatment of HIV-1 patients exposed to other integrase inhibitors, but the decision to use dolutegravir in this setting should be informed by drug resistance testing. OBJECTIVES: This study determined the extent of disagreement in predicted residual dolut...

ver descrição completa

Detalhes bibliográficos
Autor principal: Theys, Kristof (author)
Outros Autores: Abecasis, Ana (author), Libina, Pieter (author), Gomes, Perpétua (author), Cabanas, Joaquim (author), Camacho, Ricardo J. (author), Van Laethem, Kristel (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
HIV-1
dolutegravir
integrase
interpretation
resistance
treatment
Texto completo:http://hdl.handle.net/10400.26/18392
País:Portugal
Oai:oai:comum.rcaap.pt:10400.26/18392

Texto Completo

http://hdl.handle.net/10400.26/18392

Registros relacionados